HSGX vs. INGN, COCH, CLGN, RBOT, MLSS, LFWD, SMTI, KNTE, SGMT, and VXRT
Should you be buying Histogenics stock or one of its competitors? The main competitors of Histogenics include Inogen (INGN), Envoy Medical (COCH), CollPlant Biotechnologies (CLGN), Vicarious Surgical (RBOT), Milestone Scientific (MLSS), ReWalk Robotics (LFWD), Sanara MedTech (SMTI), Kinnate Biopharma (KNTE), Sagimet Biosciences (SGMT), and Vaxart (VXRT). These companies are all part of the "medical" sector.
Inogen (NASDAQ:INGN) and Histogenics (NASDAQ:HSGX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, community ranking, dividends and earnings.
Inogen received 27 more outperform votes than Histogenics when rated by MarketBeat users. However, 71.66% of users gave Histogenics an outperform vote while only 70.57% of users gave Inogen an outperform vote.
Inogen presently has a consensus price target of $7.50, indicating a potential upside of 6.69%. Given Histogenics' higher possible upside, analysts plainly believe Inogen is more favorable than Histogenics.
In the previous week, Inogen had 3 more articles in the media than Histogenics. MarketBeat recorded 3 mentions for Inogen and 0 mentions for Histogenics. Histogenics' average media sentiment score of 0.62 beat Inogen's score of 0.00 indicating that Inogen is being referred to more favorably in the media.
Inogen has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Histogenics has a beta of 3.1, indicating that its stock price is 210% more volatile than the S&P 500.
89.9% of Inogen shares are held by institutional investors. Comparatively, 40.4% of Histogenics shares are held by institutional investors. 1.0% of Inogen shares are held by company insiders. Comparatively, 19.7% of Histogenics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Histogenics has a net margin of 0.00% compared to Histogenics' net margin of -32.46%. Inogen's return on equity of -34.96% beat Histogenics' return on equity.
Histogenics has lower revenue, but higher earnings than Inogen. Histogenics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.
Summary
Inogen and Histogenics tied by winning 8 of the 16 factors compared between the two stocks.
Get Histogenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Histogenics Competitors List
Related Companies and Tools
